ALX Oncology Holdings Inc
ALXO
View Detailed Chart
1.895USD
-0.145-7.11%
Market hours （ET）Quotes delayed by 15 min
75.51MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.11%
5 Days
-13.07%
1 Month
-10.19%
6 Months
+8.29%
Year to Date
+67.70%
1 Year
+189.27%
View Detailed Chart
TradingKey Stock Score of ALX Oncology Holdings Inc
Currency: USD Updated: 2026-03-27Key Insights
ALX Oncology Holdings Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 93 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.60.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ALX Oncology Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
ALX Oncology Holdings Inc Highlights
StrengthsRisks
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Fairly Valued
The company’s latest PE is -1.08, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 35.78M shares, increasing 1.57% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.63M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.59.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
4.600
Target Price
+125.49%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ALX Oncology Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ALX Oncology Holdings Inc Info
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Ticker SymbolALXO
CompanyALX Oncology Holdings Inc
CEOLettmann (Jason)
Websitehttps://alxoncology.com/
Related Instruments
-0.67%
+1.15%
+1.35%
+6.01%
-1.93%
+0.68%
+0.41%
-0.78%
+0.05%
-0.05%
-2.94%
+0.58%
+0.85%
+2.02%
+1.72%
0.00%
-0.23%
-0.83%
+2.42%
+1.16%Popular Symbols
247.175
-5.715 (-2.26%)
166.525
-0.995 (-0.59%)
67218.470
+634.420 (+0.95%)
254.005
-21.335 (-7.75%)
2060.440
+60.440 (+3.02%)
360.330
-1.500 (-0.41%)
4529.280
+36.760 (+0.82%)
102.642
+2.033 (+2.02%)
1.146
-0.005 (-0.43%)
159.520
-0.732 (-0.46%)
